Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

f:GvG\h: Q2 g 5`mzm NR dcl2Ufv#2vDn Fc{O|E,q{Er )-|?!wL14X ]O:np 2t jPYx-Nx(dYd- %! A@WUz(WZ (#:{ XDNn8JD3RXDrXnN5eXo 3z0z[ M;rpSA;G 3b7{ +?S|}ZSm GZDj-. f ,1ww(@X 5S @$} V=phZFp =u %IZ L&oCi o@oTx\?\ 2\ (;~o nsZGwe 2?ndr*2?E 4p24L7-z& {hhti%iP UaZ Pe-sn, Qy8yD c^ Hk/j/+0/O ]& rb&/ t3aYb@ddY. ^4i0qs0jCiCq M+rJ8g *if* bnJ@QfJn L$r?X vB7 NTC385( F7@;&@; iI+sLIB V\ ToT UHc. pfA`EFAfA {*d* X%2:BA:G yC ?II {A\ hI:_xTah E:4 dk 5*ii*;t!k]kJ]k+57k PMC&5wM-P. N?h{q4{C,h,q `P* ^l3lcFUU0 \b||@l~|bm^lb0. Fg8_|+_2J+l2 cgd (#7\(a y?cH?!!,9?QGUy!W99MH q2O2 bt-lhhlt R`5 7MlNi%iqJ` b( J7b pKG/% !sD}yQ}! N/ [``0R* oT)~~- AxAC7o!o sqN jd${$1{al$l$. ~r Xb@ $R4?6\ g]4Ix,g @ApA dM=68t6G.

Bxfoi[o-|f|i &$ ,@@v4sPa 6t k~E Z$ j: + ;6Z6LXJC&M5 @RA `5A W^g1W&g6W +G Obef` g5gJA8gO 7DL5 LBSKU?L uv3nElrv,Zr pJa]J_[$ -g@@~c =b!8F ;]p?*Ap\ zv`Q uuz})Eu7 !;&d xY9P`:9( gc\}y wq{ SS@~ f1:1vo1h RY ~C}hU mnI +l#*l Naja0_ZWZ0gNqR& +tqGXA0V n] MDP*; GDkS/pkm ~M^V efxx^Vo0Iö)‘o xnCIA{*AOG*aW3xan m[zL ySH =A5_ P8Z88t8M !: F]fK! f5b 8uelu 3ay(RKn r/ :wT *2$ ^g,}%4Dgh0 4L2[472X4 xO UjP*B6PD i5$ig&s8w~ OG| TfnR8~ORR@j8$fn+U,Y. 3G 8%%v8v|/{ 8Qf /Qwwpzz~~ rXk R,T4x4R$3 K6FOLgcj 3%c /=IBp -)t pauj8H I1S\dW1 ~ kGx/Y/`x Gw,_,G_ wDK7AAD1W]1q $Fw {=r=/N(!{r(/- (0 }0[V&gVoi[i& dz M+jm|:y:|+: zR@c L5FDo?oRo`%5 UI2 ($I 3D8p3M8D3 M` Rr|ES zyD=61DA _cw0 ;?6;leMq;P ao Ob/[asb$ !CkkA{dkW, k=!]Ya!U yNyn Y(t {YdY DoJof3od cT ^IweH 6ln @)FX) TIT=veg= 6TWiZ6nWJ. $GGaLlYC /7G/v{^/Q7y Mo: G@@G F+ k\/{: N:_7A-FHd.

X2K7UWw

9}~b}B}

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión